Solid Biosciences Shares Jump After FDA Fast-Tracks SGT-0003
08 12월 2023 - 12:49AM
Dow Jones News
By Dean Seal
Shares of Solid Biosciences rose after the company said
regulators have granted their fast-track designation to its
treatment for Duchenne muscular dystrophy.
The stock was up 16% at $3.98 in early trading. Shares are still
down 26% year-to-date.
The life sciences company said Thursday that the U.S. Food and
Drug Administration granted the designation for SGT-003, its gene
therapy candidate for Duchenne muscular dystrophy.
The FDA's fast-track designation facilitates development and
expedites the review of drugs that treat serious or
life-threatening conditions and fill unmet medical needs.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
December 07, 2023 10:34 ET (15:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Solid Biosciences (NASDAQ:SLDB)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Solid Biosciences (NASDAQ:SLDB)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024
